Zim Laboratories Ltd's Q3FY25 Quarter Results
- 11 Feb 2025
Result Summary
- Zim Laboratories Ltd reported a 4.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 0.7%.
- Its expenses for the quarter were up by 2.1% QoQ and 2.2% YoY.
- The net profit increased 68.1% QoQ and decreased 16.3% YoY.
- The earnings per share (EPS) of Zim Laboratories Ltd stood at 0.8 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 98.08 | 93.46 | 97.40 | 4.9% | 0.7% |
Total Expenses | 92.38 | 90.50 | 90.40 | 2.1% | 2.2% |
Profit Before Tax | 5.70 | 2.96 | 7.01 | 92.6% | -18.7% |
Tax | 1.70 | 0.58 | 2.23 | 193.1% | -23.8% |
Profit After Tax | 4.00 | 2.38 | 4.78 | 68.1% | -16.3% |
Earnings Per Share | 0.80 | 0.50 | 1.00 | 60.0% | -20.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Zim Laboratories Ltd is a company known for its activities in the pharmaceutical sector, primarily focusing on the development, manufacture, and sale of pharmaceutical products. While specific recent developments or strategic moves in the market for Zim Laboratories are not detailed here, companies in this sector generally engage in activities such as drug formulation, contract manufacturing, and research and development aimed at improving drug delivery systems. Any recent achievements or strategic changes in direction are not specified in the available data for Zim Laboratories Ltd.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Zim Laboratories Ltd reported a total income of ₹98.08 crores. This represents a 4.9% increase from the previous quarter (Q2FY25), where the total income was ₹93.46 crores, and a slight year-over-year increase of 0.7% from Q3FY24, which had a total income of ₹97.40 crores. The modest year-over-year growth indicates relatively stable revenue generation compared to the previous year.
Profitability
During Q3FY25, Zim Laboratories Ltd's profit before tax was ₹5.70 crores, showing a significant quarter-over-quarter increase of 92.6% from ₹2.96 crores in Q2FY25. However, there was an 18.7% decrease compared to Q3FY24, where the profit before tax was ₹7.01 crores. The profit after tax for Q3FY25 was ₹4.00 crores, marking a 68.1% increase from ₹2.38 crores in Q2FY25, but a 16.3% decrease from ₹4.78 crores in Q3FY24. The earnings per share (EPS) for Q3FY25 stood at ₹0.80, which is a 60.0% increase from the previous quarter's ₹0.50, yet a 20.0% decrease from the previous year’s ₹1.00.
Operating Metrics
The total expenses for Zim Laboratories Ltd in Q3FY25 amounted to ₹92.38 crores, which was a 2.1% increase from ₹90.50 crores in Q2FY25, and a 2.2% increase from ₹90.40 crores in Q3FY24. The tax paid by the company in Q3FY25 was ₹1.70 crores, showing a significant 193.1% increase from ₹0.58 crores in Q2FY25, and a 23.8% decrease from ₹2.23 crores in Q3FY24. These figures suggest changes in the company’s tax obligations and expense management over the periods considered. The notable increases in profit before tax and profit after tax on a quarter-over-quarter basis highlight changes in operational efficiency or revenue that could impact profitability.
